This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
We give space to the following letter so that the H. K. Mulford Company cannot say that we are not treating it fairly, although much of the letter is a repetition of what has been stated before. There is no use in attempting to befog the question:
Philadelphia, Sept. 19, 1906.
To the Editor:
—Had your report of the findings on "Somnos" (Elixir Trichlorethidene Propenyl Ether, Mulford) been confined to that product, we might not have felt called on to address this letter of protest, even though prejudice is shown in the treatment of the subject.You have seen fit, in The Journal of the American Medical Association, September 15, to attack the integrity of the H. K. Mulford Company and seriously to injure our reputation as a manufacturing house. To this we take strong exception. As your charges are based on what we have said on labels and in
Somnos.. JAMA. 1906;XLVII(13):1033-1036. doi:10.1001/jama.1906.02520130057013